Hypofractionated thyroid cancer is between differentiated thyroid cancer and undifferentiated thyroid cancer. Patients with poorly differentiated thyroid cancer can undergo surgery, radiotherapy, chemotherapy or other targeted therapies, and the survival rate within 5 years can reach 60%-70%. If the patient is undifferentiated thyroid cancer, the prognosis is poorer and the survival rate within 5 years is relatively low. On the other hand, the prognosis of differentiated thyroid cancer patients is relatively better, and the survival rate of patients within 5 years is relatively high, such as the survival rate of patients with papillary carcinoma can reach 80%-90% within 5 years. Clinically, the prognosis of patients with poorly differentiated thyroid cancer is relatively poor, and the survival rate of patients is about 60%-70% in 5 years, but with the development of clinical immunotherapy and targeted therapy, patients can achieve better prognosis.